Clinicopathological and immunohistochemical markers after radical gastrectomy for gastric cancer

Hepato-Gastroenterology

Volumn 54, Issue 73, 2007, Pages 308-314

  Potrč, Stojan ^a   Gadžijev, Eldar ^a   Hajdinjak, Tine ^a   Kavalar, Rajko ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

C erB 2; Chemical markers; Gastric cancer; Immunohisto; p 53

Indexed keywords

PROTEIN P53; THYROID HORMONE RECEPTOR BETA;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH CANCER; TUMOR VOLUME;

ADENOCARCINOMA; FEMALE; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34047150708     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hermanek P, Mansmann U: Kriterien der Wertung von Prognosefaktoren: Chirurg 2001; 72:474-480.
2. Jahne J, Piso P, Meyer HJ: 1114 total gastrectomies in the surgical treatment of primary gastric adenocarcinoma - a 30-year single institution experience. Hepatogastroenterology 2001; 48(41):1222-1226.
3. Repše S, Pegan L, Kovič M: Operativno zdravljenje raka želodca. In: XXII. Tavčarjevi dnevi, Ljubljana: Medicinski razgledi, 1981; pp. 239-246.
4. Siewert JR: Magencarcinom. In: Chirurgische Gastroenterologie. 2. Aufl. Berlin (etc.): Springer, 1992; pp. 675-740.
5. Roder JD: Gastrointestinale Tumoren. Empfehlungen zur Diagnostik, Therapie und Nachsorge. 5., Vollkommene neu bearbeitete Auflage. Schriftenreihe des Tumorzentrum Muenchen 1997; pp. 116-139.
6. Sobin LH, Wittekind Ch: TNM classification of malignant tumors, 5th Edition. Berlin (etc.): Springer, 1997.
7. Beahrs OH, et al. (Eds.): AJCC Manual for Staging of Cancer. 4th Edition. Philadelphia: Lippincott, 1992.
8. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma (1st Engl. Edition). Kanehara & Co., Ltd., Tokyo, 1995.
9. Žakelj B: Standardna R0 resekcija. In: Kirurgija želodca: zbornik simpozija, Ljubljana 1995. Ljubljana: Klinični center, Kirurške klinike, Kirurška šola, 1995; pp.113-115.
10. Jelenc F, Repše S, Omejc M, Juvan R: Sistematična limfadenektomija. In: Kirurgija želodca: zbornik simpozija, Ljubljana 1995. Ljubljana: Klinični center, Kirurške klinike, Kirurška šola, 1995; pp. 116-120.
11. Roder JD: Gastrointestinale Tumoren. Empfehlungen zur Diagnostic Therapie und Nachsorge. 5., Vollkommene neu bearbeitete Auflage. Schriftenreihe des Tumorzentrum Muenchen 1997; p. 42.
12. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K, Yamamoto T: Localization of a V-erbB-related gene, C-erbB-2, on the human chromosome and its amplification in MKN-7 gastric cancer cell line. Mol Cell Biol 1986; 6:955-958.
13. Siewert JR: Editorial: Prognosefaktoren für Patienten und Chirurgen. Chirurg 2001; 72:473.
14. Alvarez MG, Besa PC: Molecular basis of cancer and clinical applications. Surg Clin North Am 2000; 80:443-457.
15. Yokota J, Yamamoto, T, Toyoshima K, Terada M, Sugimura T, Battifora H, Cline MJ: Amplification of C-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986; 1:765-767.
16. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE: Correlation of C-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48:1238-1243.
17. Barash P, Cullen B, Stoelting R: Preoperative evaluation. In: Fleisher L: Clinical Anesthesia. 3th Edition. Philadelphia - New York: Lippincott-Raven publishers, 1996; p. 444.
18. Fukunaga M, Monden T, Nakanishi H, Ohue M, Fukuda K, Tomita N, Shimano T, Mori T: Immunohistochemical study of p53 in gastric carcinoma. Am J Clin Pathol 1994; 101: 177-180.
19. Hruban RH, Westra WH: Surgical pathology dissection: an illustrated guide. New York: Springer, 1996.
20. th Edition. St. Louis (etc.): Mosby, 1996; pp. 2710-2711.
21. Golouh R: Imunohistokemične metode. Imunohistokemič na delavnica. Ljubljana: Onkološki inštitut, Oddelek za patologijo. 1997; pp. 15-17.
22. Kljun A: Imunohistokemične metode. Imunohistokemična delavnica. Ljubljana: Onkološki inštitut, Oddelek za patologijo. 1997; pp. 1-13.
23. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-481.
24. Cox DR: Regression models and life-tables: J R Stat Soc B 1972; 34:187-220.
25. Incidenca raka v Sloveniji 1997. Poročilo RR št. 39, Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2000.
26. Siewert JR, Bottcher K, Stein HJ, Roder JD: Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228:449-461.
27. st Edition. Berlin (etc.): Springer, 1995; p. 290.
28. Siewert JR, Bottcher K, Roder JD Busch R, Hermanek P, Meyer HJ: Prognostic relevance of systemic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group: Br J Surg 1993; 80:1015-1018.
29. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ: Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 1993; 72:2089-2097.
30. Bonenkamp JJ, Songun I, Hermans J, Sasko M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345:745-748.
31. Wagener C: Molekulare Onkologie: Entstehung und Progression maligner Tumoren. 2. Aufl., Stuttgart, New York: Georg Thieme, 1999; pp. 24-35.
32. Blok P, Craanen ME, Dekker W, Offerhaus GJ, Tytgat GN: No evidence for c-erbB-2 overexpression in gastric carcinogenesis. Histopathology 1998; 32:335-339.
33. Wu MS, Shun CT, Sheu JC, Wang HP, Wang JT, Lee WJ, Chen CJ, Wang TH, Lin JT: Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages. J Gastroenterol Hepatol 1998; 13:305-310.
34. Imazeki F, Omata M, Nose H, Ohto M, Isono K: p53 gene mutations in gastric and esophageal cancers: Gastroenterology 1992; 103:892-896.
35. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S: p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 1993; 54:759-764.
36. Wei Z, Wu Y, Zhai Z: Immunohistochemical study of p53, c-erbB-2 and nm-23 proteins in human gastric cancer. Zhonghua Zhong Liu Za Zhi 1997; 19:378-381.
37. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85:1894-902.
38. Gurel S, Dolar E, Yerci O, Samli B, Ozturk H, Nak SG, Gulten M, Memik F: The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res 1999; 27:74-78.
39. Tolbert D, Fenoglio-Preiser C, Noffsinger A, De Voe G, MacDonald J, Benedetti J, Stemmermann GN: The relation of p53 gene mutations to gastric cancer subsite and phenotype. Cancer Causes Control 1999; 10:227-231.
40. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K: Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993; 67:589-593.
41. Maeda K, Kang SM, Onoda N, Ogawa M, Sawada T, Naka ta B, Kato Y, Chung YS, Sowa M: Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology 1998; 55:594-599.
42. Liu XP, Tsushimi K, Tsushimi M, Oga A, Kawauchi S, Furuya T, Sasaki K: Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathol Int 2001; 51:440-444.
43. Diez M, Medrano MJ, Gutierrez A, Muguerza JM, Hernandez P, Lozano O, Noguerales F, Ruiz A, Granell J: P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy. Anticancer Res 2000; 20:3929-3933.
44. Sanz-Ortega J, Steinberg SM, Moro E, Saez M, Lopez JA, Sierra E, Sanz-Esponera J, Merino MJ: Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-erbB-2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 2000; 15:455-462.